Kruzliak Peter, Maruyama Junko, Maruyama Kazuo
Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
Department of Anesthesiology and Critical Care Medicine, Mie University School of Medicine, Mie, Japan; Department of Clinical Engineering, Suzuka University of Medical Science, Mie, Japan.
Vitam Horm. 2014;96:407-24. doi: 10.1016/B978-0-12-800254-4.00016-7.
Pulmonary hypertension is a condition characterized by vasoconstriction, vascular cell proliferation, inflammation, microthrombosis, and vessel wall remodelation. Pulmonary endothelial cells produce vasoactive substances with vasoconstrictive as well as vasodilatative effects. The imbalance of these endothelium-derived vasoactive substances induced by endothelial dysfunction is very important in the pathogenesis of PH. One of most important substances with vasodilatative effect is nitric oxide. We provide a comprehensive insight into role of NO in the pathgenesis of PH and discuss perspectives and challenges in PH therapy based on NO administration.
肺动脉高压是一种以血管收缩、血管细胞增殖、炎症、微血栓形成和血管壁重塑为特征的病症。肺内皮细胞产生具有血管收缩和血管舒张作用的血管活性物质。内皮功能障碍引起的这些内皮源性血管活性物质的失衡在肺动脉高压的发病机制中非常重要。具有舒张血管作用的最重要物质之一是一氧化氮。我们全面深入地探讨了一氧化氮在肺动脉高压发病机制中的作用，并讨论了基于一氧化氮给药的肺动脉高压治疗的前景和挑战。
